Lantheus (NASDAQ:LNTH) Rating Lowered to “Hold” at StockNews.com

Lantheus (NASDAQ:LNTH) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Thursday.

Several other brokerages have also recently commented on LNTH. B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Finally, Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Stock Performance

Shares of LNTH opened at $90.52 on Thursday. The company’s 50-day simple moving average is $103.43 and its 200-day simple moving average is $96.53. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a market capitalization of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its position in shares of Lantheus by 10.4% in the 1st quarter. Russell Investments Group Ltd. now owns 37,708 shares of the medical equipment provider’s stock valued at $2,347,000 after purchasing an additional 3,560 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Lantheus by 8.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 21,088 shares of the medical equipment provider’s stock worth $1,313,000 after acquiring an additional 1,670 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after acquiring an additional 389,828 shares during the period. CANADA LIFE ASSURANCE Co raised its position in Lantheus by 30.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 50,078 shares of the medical equipment provider’s stock valued at $3,116,000 after purchasing an additional 11,696 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Lantheus during the 1st quarter worth $1,432,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.